Utilization of Michigan Cancer Genetics Services, 2007—2011: Findings from the *BRCA* Clinical Genetic Counseling Database

Patients whose personal and/or family history of cancer is associated with an increased risk for deleterious mutations in *BRCA1* or *BRCA2* genes should be referred for genetic counseling and evaluation for testing.[1-3] Since 2008, the Michigan Department of Community Health (MDCH) Cancer Genomics Program has developed methods to promote the translation of guidelines for *BRCA* counseling and testing into clinical and public health practice as part of cooperative agreements with the Centers for Disease Control and Prevention. When this work began, little was known about the use of these services in Michigan. MDCH met this need through development of a statewide network of clinical facilities providing *BRCA* counseling. These tables provide an overview of characteristics of patients utilizing these services, referring providers, and the services received.

MDCH identified 11 clinical facilities in Michigan with board-certified genetics professionals providing *BRCA* counseling between October 2007 and March 2011. One facility, with an out-of-state genetics provider, was not able to provide data using our reporting system; therefore 10 out of 11 facilities participated in the MDCH clinical network.

Participating facilities include Beaumont Health System Cancer Genetics Program, Henry Ford Health System, InformedDNA*, Karmanos Cancer Institute Genetics Service, Michigan State University Division of Clinical Genetics, Oakwood Healthcare System's Genetic Risk Assessment for Cancer Clinic, Providence Hospital Medical Genetics, Spectrum Health Cancer Genetics Program, University of Michigan Cancer Genetics Clinic, and University of Michigan Breast and Ovarian Cancer Risk and Evaluation Program.

Following IRB review, each clinical facility provided a de-identified, limited dataset on all patients receiving *BRCA* counseling during the period of interest. These data include patient demographics, type of referring provider, personal and family histories of cancer, insurance type, *BRCA* tests ordered and results, and reasons for not testing, if applicable. The surveillance system originally used a Microsoft Access database featuring drop-down menus and tabs for user-friendly navigation; this has since been converted to an online database with a similar format.

* Phone counseling service providing data on patients residing in Michigan only

1. US Preventive Services Task Force. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement. Ann Intern Med *2005* Sep 6; 143:355-361.
2. Healthy People 2020, Objective G HP2020-2. Accessed July 5, 2012. http://www.healthypeople.gov/hp2020/objectives/TopicAreas.aspx
3. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High Risk Assessment: Breast and Ovarian. Version 1.2012, 05/02/2012.

Utilization of Michigan Cancer Genetics Services, 2007—2011: Findings from the *BRCA* Clinical Genetic Counseling Database



This project is supported by Cooperative Agreement # 5U38GD000054 from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.